Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Mural Oncology plc

We know that drug development is both an art and a science.

The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us.

Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living.

Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. 

Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies.  

We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective.

Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)


Mural Oncology

Today marks a notable milestone as Mural Oncology officially launches as an independent, publicly traded, clinical-stage immuno-oncology company. Tomorrow, find us on Nasdaq as $MURA.

Mural's dedication to advancing our pipeline of novel engineered cytokine immunotherapies with our lead candidate, nemvaleukin alfa, is backed by a strong foundation of $275 million in committed funding, and a clear vision to reimagine cytokine-based immunotherapies for the treatment of cancer. 

Our mission is simple: to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Learn more:  https://bit.ly/47AUnhN #oncology #biotechnology #innovation #immunooncology #Nasdaq

	Dec '21	Dec '22	Dec '23
average inventory			75K -
average payables		6.78M -	4.47M 34.04%
average receivables			2.77M -
book value per share	-1.07 -	-1.30 21.13%
capex per share	-0.26 -	-0.33 25.68%
capex to depreciation	-2.97 -	-3.58 20.29%	-1.34 62.42%
capex to operating cash flow	0.03 -	0.03 16.79%	0.02 45.64%
capex to revenue
cash per share	-1.52 -	-1.16 23.39%
days of inventory on hand
days payables outstanding
days sales outstanding
debt to assets	0.72 -	0.57 20.31%	0.05 91.34%
debt to equity	-1.42 -	-0.90 36.75%	0.06 106.36%
dividend yield
earnings yield	-2.77 -	-3.15 14.02%
enterprise value	114.03M -	102.19M 10.38%	-255.84M 350.37%
enterprise value over ebitda	-0.66 -	-0.53 19.51%
ev to operating cash flow	-0.73 -	-0.61 16.72%	1.32 317.29%
ev to sales
free cash flow per share	-9.65 -	-10.43 8.10%
free cash flow yield	-2.54 -	-2.75 8.10%
graham net net	-4.69 -	-4.48 4.47%
graham number	15.92 -	18.71 17.52%
income quality	0.89 -	0.89 0.54%	0.94 5.42%
intangibles to total assets	0 -	0	0
interest coverage
interest debt per share	1.52 -	1.16 23.39%
inventory turnover
invested capital	-1.42 -	-0.90 36.75%	0.06 106.36%
market cap	63.41M -	63.41M 0%
net current asset value	-48.75M -	-50.59M 3.77%	239.41M 573.24%
net debt to ebitda	-0.29 -	-0.20 31.19%
net income per share	-10.51 -	-11.99 14.02%
operating cash flow per share	-9.39 -	-10.10 7.61%
payables turnover
receivables turnover
research and ddevelopement to revenue
return on tangible assets	-5.00 -	-5.93 18.62%
revenue per share
roe	9.81 -	9.24 5.87%
roic	-5.36 -	-11.69 118.06%
sales general and administrative to revenue
shareholders equity per share	-1.07 -	-1.30 21.13%
stock based compensation to revenue
tangible asset value	-17.88M -	-21.66M 21.13%	263.82M 1,318.22%
tangible book value per share	-1.07 -	-1.30 21.13%
working capital	-29.01M -	-36.74M 26.67%	248.32M 775.83%

MURA

COM:MURALONCOLOGY

Mural Oncology plc

Last Close

3.37

22/11 21:00

Market Cap

54.25M

Beta: -

Volume Today

35.85K

Avg: -

Preview